XML Financial LLC Increases Stock Holdings in Pfizer Inc. (NYSE:PFE)

XML Financial LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 1.5% during the third quarter, Holdings Channel reports. The firm owned 182,019 shares of the biopharmaceutical company’s stock after purchasing an additional 2,690 shares during the quarter. XML Financial LLC’s holdings in Pfizer were worth $5,268,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. Olistico Wealth LLC purchased a new stake in Pfizer during the 2nd quarter worth about $25,000. MFA Wealth Advisors LLC purchased a new position in Pfizer in the second quarter worth approximately $29,000. Quarry LP acquired a new stake in shares of Pfizer in the 2nd quarter valued at $31,000. Financial Connections Group Inc. purchased a new stake in shares of Pfizer during the 2nd quarter worth $34,000. Finally, ESL Trust Services LLC purchased a new stake in Pfizer during the 1st quarter worth about $37,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Transactions at Pfizer

In other news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.06% of the company’s stock.

Pfizer Stock Down 1.2 %

PFE opened at $26.72 on Friday. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $31.54. The business has a 50 day moving average price of $28.89 and a two-hundred day moving average price of $28.63. The company has a quick ratio of 0.60, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a market cap of $151.42 billion, a PE ratio of 36.11, a P/E/G ratio of 0.87 and a beta of 0.67.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. During the same quarter in the prior year, the business earned ($0.17) earnings per share. The company’s quarterly revenue was up 31.2% compared to the same quarter last year. As a group, research analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.29%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s payout ratio is 227.03%.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on PFE. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Barclays upped their target price on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. UBS Group upped their price objective on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Finally, Sanford C. Bernstein started coverage on Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. Eight equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.58.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.